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Abstract: Contractile restoration of myocardial scars remains a challenge with important clinical implications. Here, 
a combination of porous elastomeric membrane, peptide hydrogel, and subcutaneous adipose tissue-derived pro-
genitor cells (subATDPCs) was designed and evaluated as a bioimplant for cardiac regeneration in a mouse model 
of myocardial infarction. SubATDPCs were doubly transduced with lentiviral vectors to express bioluminescent-
fluorescent reporters driven by constitutively active, cardiac tissue-specific promoters. Cells were seeded into an 
engineered bioimplant consisting of a scaffold (polycaprolactone methacryloyloxyethyl ester) filled with a peptide 
hydrogel (PuraMatrix™), and transplanted to cover injured myocardium. Bioluminescence and fluorescence quantifi-
cations showed de novo and progressive increases in promoter expression in bioactive implant-treated animals. The 
bioactive implant was well adapted to the heart, and fully functional vessels traversed the myocardium-bioactive 
implant interface. Treatment translated into a detectable positive effect on cardiac function, as revealed by echocar-
diography. Thus, this novel implant is a promising construct for supporting myocardial regeneration.
Keywords: Cardiac regeneration, subcutaneous ATDPCs, self-assembling peptide hydrogel, elastomeric mem-
brane, RECATABI
Introduction
Acute myocardial infarction (MI) is a leading 
cause of mortality all over the world that occurs 
due to interruption of the blood supply to the 
heart [1]. As a consequence, a massive loss of 
cardiomyocytes occurs and a fibrotic scar is 
formed, leading to non-contractile myocardium 
and enlargement of the left ventricle [2, 3]. 
Given the limited regenerative capacity of the 
myocardium after ischemic damage [4], cellular 
cardiomyoplasty has emerged as a promising 
therapeutic strategy [5]. Although preclinical 
studies and clinical trials of cell transplantation 
for cardiac regeneration have demonstrated 
certain beneficial effects and safety, these 
treatments were not as effective as expected 
due to poor cell retention and survival in the 
contracting myocardium [6-14]. Aside from 
choosing the optimal cell type for cardiac regen-
eration, the ideal route of cell delivery and the 
optimal dose remain controversial [15].
New strategies have emerged to circumvent 
these difficulties, such as the development of 
cardiac tissue engineering and myocardial bio-
prosthesis [16]. In myocardial bioprosthesis, 
functional cardiac tissue replacements are cre-
ated from biological and synthetic materials, 
often in combination with regenerative cells 
and other biochemical factors [17-20]. The goal 
is to generate a suitable environment for cell 
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survival within the hostile conditions of the 
ischemic myocardium, and to differentiate 
these cells into cardiac or endothelial lineages 
with the ultimate purpose of regenerating the 
damaged myocardium. Accordingly, the RECA- 
TABI (Regeneration of Cardiac Tissue Assisted 
by Bioactive Implants) consortium has designed 
and produced novel bioactive implants using 
innovative biomaterial combinations that may 
improve cell delivery, survival, migration, and 
differentiation into newly functional myocardial 
tissue (http://www.recatabi.com/).
We developed a bioactive implant consisting of 
partially biodegradable elastomeric mem-
branes that act as a scaffold; the membranes 
are filled with a self-assembling peptide hydro-
gel and cells with cardiac regenerative poten-
tial, subcutaneous adipose tissue-derived pro-
genitor cells (subATDPCs) [21-24]. Here, we 
evaluated the effect of this novel bioactive 
implant on cell survival and differentiation, and 
analyzed tolerance and functional benefits of 
the implant in a mouse model of MI.
Material and methods
Isolation and culture of subATDPCs
Cells were isolated from subcutaneous adipose 
tissue between the skin and the sternum of 
patients undergoing cardiac surgery. Informed 
consent was obtained from all subjects, and 
the study protocol conformed to the principles 
outlined in the Declaration of Helsinki. Biopsy 
samples were processed and cells were isolat-
ed as described previously [25, 26]. Adhered 
cells were cultured to subconfluence under 
standard conditions (37°C and 5% CO2).
Genetic labeling of subATDPCs with biolumi-
nescent and fluorescent reporters regulated 
by the human cardiac troponin I promoter 
(hcTnIp) or the cytomegalovirus promoter 
(CMVp)
SubATDPCs were co-transduced (2 × 106 trans-
ducing units/mL, multiplicity of infection=21, 
48 h) with the following lentiviral vectors: (1) 
CMVp-RLuc-mRFP1, which contains a chimeric 
construct of the Renilla reniformis luciferase 
(RLuc) reporter and monomeric red fluorescent 
protein (mRFP1) in a pHR lentiviral vector under 
transcriptional control of the CMV promoter 
[27], and (2) hcTnIp-PLuc-eGFP, a fusion report-
er vector comprised of the Photinus phyralis 
luciferase (PLuc) and enhanced green fluores-
cent protein (eGFP) coding regions under the 
transcriptional control of hcTnIp, which is tran-
scriptionally active in cardiomyocytes [23]. 
Cells expressing mRFP1 were selected by fluo-
rescence-activated cell sorting.
Generating elastomeric membranes (micropo-
rous scaffolds)
Poly (caprolactone 2-(methacryloyloxy)ethyl est- 
er) (PCLMA) scaffolds with spherical intercon-
nected pores were prepared as previously 
described [21]. Briefly, the monomeric solution 
was mixed with 1 wt% of benzoin (98%, 
Scharlau) as photo-initiator and 2 wt% of ethyl-
eneglycol dimethacrylate (98%, Aldrich) as 
cross-linker, injected into a porogen template 
obtained by sintering poly(methyl methacrylate) 
microspheres 90 ± 10 μm in diameter (dp 300, 
Colacryl), polymerized for 24 h under ultraviolet 
light, and post-polymerized for another 24 h in 
an oven at 90°C. After polymerization, the 
porogen was eliminated by dissolution with 
acetone (Scharlab). The acetone was then slow-
ly exchanged for water, and the resulting scaf-
folds were dried under vacuum. PCLMA scaf-
folds were cut into 3 × 3 × 0.5 membranes and 
sterilized with gamma radiation before cell 
seeding.
Development of the bioactive implants: cell-
seeded elastomeric membranes prefilled with 
RAD16-I self-assembling peptide
The self-assembling peptide RAD16-I (Pura- 
Matrix™ 1% (w/v), BD Biosciences) was used to 
fill the pores in the PCLMA scaffolds. Prior to 
use, RAD16-I was sonicated for 30 min at 25°C, 
applying 30 W to reduce its viscosity (Bandelin). 
The elastomeric membranes were then embed-
ded in a 0.15% solution of RAD16-I nanofiber 
peptide using a syringe as a vacuum system. 
Next, 0.5 × 106 subATDPCs suspended in 10% 
sucrose were seeded inside the construct and 
incubated with soft shaking for 30 min. Sucrose 
solution without cells was added to the control 
membranes. Then, 160 µL of culture medium 
was used to increase the ionic strength of the 
system and thus to induce the self-assembly of 
the peptides into nanofibers. Finally, the con-
structs were cultured under standard condi-
tions (37°C and 5% CO2) for one day before 
implantation.
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MI model and bioimplant delivery
A total of 25 female severe combined immuno-
deficiency mice (20-25 g; Charles River 
Laboratories, Inc.) were used for this study. The 
animals were randomly assigned to one of the 
following four groups: (1) bioimplant implanta-
tion and no MI induction (the sham group, n=6), 
(2) MI induction and no bioimplant (the control-
MI group, n=5), (3) MI induction and scaffold 
implantation (the MI-scaffold group, n=5), and 
(4) MI induction and bioimplant implantation 
(the MI-bioimplant group, n=9).
MI was induced as previously described [25]. 
Briefly, each animal was intubated and anes-
thetized with a mixture of O2/isoflurane and 
mechanically ventilated. The heart was exposed 
and the left anterior descending coronary 
artery was permanently occluded. Bioimplants 
or scaffolds were then implanted using synthet-
ic surgical glue (Glubran®2) on the healthy 
myocardium. Four weeks post-implantation, 
hearts were arrested in diastole with cardiople-
gic solution (68.4 mM NaCl, 59 mM KCl, 11.1 
mM glucose, 1.9 mM NaHCO3, 29.7 mM 
2,3-butanedione monoxime, 1000 U heparin), 
excised, fixed, cryopreserved in 30% sucrose in 
phosphate-buffered saline, embedded in Tiss- 
ue-Tek O.C.T. (Sakura), and snap-frozen in liquid 
nitrogen-cooled isopentane. Tissue blocks 
were stored at -80°C until sectioning. All animal 
handling procedures were approved by the 
Institutional Animal Care and Use Committee 
and conformed to the Guide for the Care and 
Use of Laboratory Animals of the Institute of 
Laboratory Animal Research (NIH Pub. No. 
86-23, Revised 1996).
Non-invasive bioluminescence imaging (BLI) of 
luciferase activity and fluorescence detection 
in the bioimplant
For in vivo BLI, anesthetized mice bearing a bio-
implant seeded with transduced cells were 
intraperitoneally injected with 150 μL of lucif-
erin (16.7 mg/mL in physiological serum) 
(Caliper) for PLuc detection. The next day, ani-
mals were intravenously (tail vein) injected with 
25 μL of benzyl coelenterazine (1 mg/mL in 
50/50 propilene glycol/ethanol; Nanolight 
Technology) diluted in 125 μL for the detection 
of RLuc-expressing cells. Mice were monitored 
immediately after implantation and at 1, 2, and 
3 weeks post-implantation. Fluorescence was 
also detected from the excised hearts immedi-
ately after sacrifice. Quantification and analysis 
of photons recorded and fluorescence in imag-
es were performed using the Caliper image 
analysis software (Caliper).
Cardiac function determination
Transthoracic echocardiography was per-
formed under light sedation (1% isoflurane in 
O2) before surgery (baseline), two days after 
surgery (MI), and at 4 weeks after surgery (pre-
sacrifice). A digital ultrasound system (Vevo 
2100 Imaging System, VisualSonics) equipped 
with an 18-38 MHz linear-array transducer was 
used to take measurements. Images were 
obtained in B-Mode and M-Mode in the para-
sternal long-axis and short-axis views. All imag-
es were acquired and measured by an investi-
gator who was blinded to the treatment groups. 
Conventional functional parameters were mea-
sured, including left ventricle fractional short-
ening, left ventricle ejection fraction (LVEF), left 
ventricle anterior wall, left ventricle posterior 
wall, left ventricle end-diastolic dimension, and 
left ventricle end-systolic dimension.
Histological evaluation
Mouse hearts were transversally sliced into two 
segments at the ligation level. Eight serial cryo-
sections (spaced 200 µm apart) from the api-
cal segment were stained with Masson’s tri-
chrome. All sections were blindly examined and 
photographed using a SMZ 800 stereoscope 
(Nikon).
Immunohistochemistry
Mouse heart cryosections were incubated with 
primary antibodies against cardiac troponin I 
(cTnI; 2 μg/mL; Abcam). Sections were also 
incubated with RFP and GFP antibodies (2 μg/
mL; Abcam) to enhance the detection of trans-
duced cells. Nuclei were counterstained with 
Hoechst 33342, and results were analyzed 
with a Leica TCS SP2 confocal microscope.
Fluorescence angiography
Fluorescein isothiocyanate (FITC)-dextran (Sig- 
ma) was used as a fluorescent tracer of micro-
vascular structures in bioimplants and hearts. 
Two hundred microliters of FITC-dextran (10 
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mg/mL) were injected through the lateral tail 
vein of anesthetized mice 10 min before sacri-
fice. Laser confocal microscopy (Axio-Observer 
Z1, Zeiss) was used for section analysis.
Figure 1. BLI and fluorescent evaluation of cTnI expression and survival of subATDPCs implanted over the mouse 
infarcted myocardium. A: Representative BLI of labeled subATDPCs within the bioactive implant displays the lucif-
erase signal from the cell differentiation reporter (PLuc-eGFP) that is regulated by the hcTnI promoter. Images of 
the hcTnI-specific reporter are superimposed on black-and-white dorsal images of the recipient animal. Color bars 
illustrate relative light intensities from PLuc. B: Histograms of the PLuc/RLuc ratio calculated from photon fluxes 
recorded via BLI from bioactive implant-treated infarcted animals. C: Representative fluorescence images from 
subATDPCs within the bioactive implant pre-implantation and post-sacrifice over the excised hearts. Upper images 
show fluorescence from the cell differentiation reporter (PLuc-eGFP) regulated by hcTnIp (green). Bottom images 
are representative of constitutive fluorescence from the cell-number reporter (CMVp-RLuc-mRFP1; red). Color bars 
illustrate the relative fluorescence intensities from eGFP (green) and RFP (red). D: Immunofluorescence staining of 
mouse heart cross-sections shows the bioactive implant filled with human subATDPCs. Transplanted cells were de-
tected via RFP immunostaining (red), and cTnI expression was detected with anti-eGFP (green) and anti-cTnI (white) 
antibodies. (BI, bioactive implant; My, myocardium). Scale bars, 20 μm.
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Statistical analysis
The statistical significance of bioluminescence 
and cardiac-function parameters was evaluat-
ed via analysis of variance (factors: time and 
treatment) and a Greenhouse correction was 
applied. Results are presented as mean stan-
dard error of the mean. P-values<0.05 were 
considered significant. All analyses were per-
formed with SPSS Statistics version 19 (IBM).
Results
SubATDPCs express hcTnI after implantation 
over infarcted myocardium by means of a 
biosynthetic bioactive implant
In these experiments, we sought to monitor 
cardiomyogenic lineage differentiation and sur-
vival of subATDPCs in vivo, using non-invasive 
BLI. For this purpose, cells were transduced 
using lentiviral vector CMVp-RLuc-mRFP1 to 
express the RLuc-RFP reporter under the regu-
lation of the CMV promoter, a reporter of cell 
number. Then, to monitor cardiomyogenic lin-
eage differentiation, positively transduced cells 
expressing RLuc-RFP were selected by fluores-
cence-activated cell sorting and transduced 
with lentiviral vector hcTnIp-PLuc-eGFP to 
express the PLuc-eGFP reporter under the reg-
ulation of hcTnIp. Doubly transduced cells were 
loaded into the bioactive implant and delivered 
to the infarcted area in a mouse model of MI.
Photon counts revealed an increase in the ratio 
between hcTnIp-regulated PLuc and CMV-
regulated RLuc activities in infarcted (Figure 
1A and 1B) and sham-infarcted (data not 
shown) animals. hcTnI was expressed de novo 
as early as one week post-implantation, with 
expression increasing up to 9-fold at 3 weeks. 
Interestingly, an important RFP signal was 
detected in excised hearts, indicating the reten-
tion and local presence of the implanted cells 
after sacrifice (Figure 1C). In concordance with 
BLI, GFP was also detected, indicating hcTnI 
expression at the time of sacrifice. Comparisons 
of the GFP/RFP ratio pre-implantation and at 
sacrifice demonstrated a 16-fold increase in 
hcTnI expression.
Immunodetection of RFP in histological analy-
ses of excised heart cross-sections revealed 
the presence of subATDPCs in the bioactive 
implant up to 4 weeks after implantation in all 
analyzed groups (Figure 1D). Additionally, to 
relate hcTnI gene and protein expression, 
immunostaining against hcTnI protein was per-
formed in all cell-treated animals. RFP, GFP, 
and hcTnI proteins co-localized in implanted 
subATDPCs (Figure 1D), validating the BLI anal-
ysis and providing evidence of differentiation 
into the cardiac lineage. However, no implanted 
subATDPCs were observed in the myocardium 
of infarcted or sham-treated animals, indicat-
ing an absence of migration from the bioactive 
implant to the underlying heart.
Adaptability and vascularization of the bioim-
plant in the mouse model of MI
Macroscopic and histological observations of 
excised hearts and cross-sections demonstrat-
ed that the bioactive implants were perfectly 
adapted to the mouse myocardium covering 
the infarcted scar (Figure 2A and 2B). Moreover, 
RFP-expressing subATDPCs were observed 
inside the bioactive implant and displayed the 
same spindle-shaped morphology observed in 
culture (Figure 2C and 2C’). Taken together, our 
observations indicate that the PCLMA elasto-
meric membrane confers a suitable environ-
ment for subATDPC survival.
To determine whether functional vessel con-
nections had been established between the 
bioactive implant and the myocardium, animals 
received FITC-dextran through the tail vein prior 
to sacrifice. The bioactive implant was fully vas-
cularized in all cases, including control animals 
that did not receive cell transplants (Figure 2D 
and 2E); the vessels were connected to the cir-
culatory system (Figure 2D, arrowhead) and 
were functional (Figure 2D and 2E).
The bioactive implant positively affects global 
cardiac function
To evaluate the effect of the bioactive implant 
on cardiac function in the mouse infarcted 
myocardium, echocardiographic analyses were 
performed. Conventional measures of global 
left ventricle function, such as LVEF, revealed 
that infarcted animals treated with the bioac-
tive implants with or without cells presented 
functional improvement at sacrifice (48% and 
47%, respectively) (Table 1, Figure 3A and 3B). 
LVEF relative changes, expressed as differenc-
es between values post-infarction and at sacri-
fice, were higher in control-MI animals (-17.5%) 
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than in MI-bioimplant animals (-14.1%) or in the 
MI-scaffold group (-13.6%) (Figure 3C). Analysis 
of variance revealed that the LVEF of cell-treat-
ed mice did not significantly differ from that of 
non-infarcted (sham-treated) animals (P=0.10).
Discussion
Cardiac tissue engineering and myocardial bio-
prosthesis have evolved over recent years as 
therapeutic alternatives for replacing damaged 
tissue after MI. These approaches propose the 
in vitro generation of artificial cardiovascular 
tissue platforms with similar characteristics to 
the heart for use as a myocardial replacement 
or for cell and molecule delivery [28]. Numerous 
materials with defined composition and proper-
ties as well as various cell types have been 
studied, but the optimal combination has not 
yet been identified.
We have generated and tested a platform con-
sisting of partially biodegradable elastomeric 
membranes (PCLMA) loaded with peptide 
Figure 2. Adaptability and vascularization of the bioimplant in the mouse model of MI. A: Representative image of a 
heart excised from a bioactive implant-treated animal. Dotted lines indicate localization of the implant. Scale bars, 
1 mm. B: Masson’s trichrome staining in a heart cross-section reveals the presence of a myocardial scar (blue) and 
the good adaptability of the bioactive implant. Scale bars, 1 mm. C: Cells inside the bioactive implant three days 
post-implantation were detected via the constitutively active reporter CMVp-RLuc-mRFP1 (red). C’: Detail of the 
spindle-shape morphology of subATDPCs. Scale bars, 25 μm. D and E: Functional vessel detection with FITC-dextran 
(green) in mice treated with subATDPCs. Arrowheads indicate a vessel connection between the mouse myocardium 
and the bioactive implant in a cell-treated animal. Nuclei were counterstained with Hoechst 33342. Scale bars, 20 
μm and 250 μm.
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Table 1. Cardiac function parameters
Sham Control-MI MI-Scaffold MI-Bioimplant
Baseline Post-op 30 days Baseline Post-MI 30 days Baseline Post-MI 30 days Baseline Post-MI 30 days
AWd (mm) 0.9 ± 0.1 1.1 ± 0.2 0.9 ± 0.2 0.7 ± 0.2 0.8 ± 0.3 0.7 ± 0.2 0.8 ± 0.3 1.1 ± 0.2 0.8 ± 0.2 1.0 ± 0.3 1.0 ± 0.2 0.9 ± 0.1
AWs (mm) 1.3 ± 0.2 1.4 ± 0.4 1.2 ± 0.2 1.2 ± 0.1 1.2 ± 0.6 0.8 ± 0.2 1.0 ± 0.2 1.2 ± 0.3 1.1 ± 0.2 1.1 ± 0.4 1.4 ± 0.2 1.3 ± 0.2
PWd (mm) 1.0 ± 0.2 0.9 ± 0.1 0.9 ± 0.1 0.8 ± 0.2 0.7 ± 0.2 1.0 ± 0.2 0.9 ± 0.1 0.8 ± 0.2 1.0  ± 0.2 0.7 ± 0.1 0.9 ± 0.2 1.0 ± 0.2
PWs (mm) 1.6 ± 0.3 1.3 ± 0.1 1.2 ± 0.2 1.4 ± 0.3 1.1 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 0.9 ± 0.3 1.2 ± 0.1 1.3 ± 0.2 1.1 ± 0.3 1.2 ± 0.1
LVEDD (mm) 2.7 ± 0.6 2.9 ± 0.3 3.5 ± 0.1 2.4 ± 0.6 2.6 ± 0.4 3.6 ± 0.5 3.2 ± 0.2 2.5 ± 0.7 3.7 ± 0.3 2.7 ± 0.5 2.8 ± 0.3 3.9 ± 0.2
LVESD (mm) 1.4 ± 0.4 1.6 ± 0.2 2.3 ± 0.2 1.2 ± 0.5 1.7 ± 0.2 2.7 ± 0.7 1.9 ± 0.3 1.8 ± 0.3 2.9 ± 0.3 1.3 ± 0.4 1.9 ± 0.2 3.0 ± 0.2
LVFS (%) 48.5 ± 6.9 45.1 ± 2.8 34.0 ± 3.9 46.2 ± 7.0 30.4 ± 7.7 20.4 ± 2.3 42.7 ± 12.0 31.7 ± 8.1 23.1 ± 4.4 48.9 ± 5.4 32.6 ± 5.8 24.1 ± 4.5
LVEF (%) 81.1 ± 6.9 77.9 ± 3.0 63.9 ± 5.6 78.86 ± 7.5 59.8 ± 11.3 42.3 ± 4.3 73.7 ± 12.7 60.5 ± 11.5 47.0 ± 7.7 81.8 ± 5.1 62.4 ± 7.6 48.3 ± 7.4
Values are shown as mean ± SD. AWd, anterior wall diastole; AWs anterior wall systole; PWd, posterior wall diastole; PWs, posterior wall systole; LVEDD, left ventricle end-diastolic dimension; LVESD, left 
ventricle end-systolic dimension; LVFS, left ventricle fractional shortening; LVEF, left ventricle ejection fraction; Post-op, post-operation.
Bioactive implant for cardiac regeneration
298 Am J Transl Res 2014;6(3):291-301
hydrogel (PuraMatrix™) and subATDPCs [23], 
which display cardiac regenerative capacity. 
These three components form a bioactive 
implant that supports implanted cells and pro-
vides a hospitable environment for their surviv-
al and differentiation. Here we tested the thera-
peutic efficacy of this bioactive implant in mice, 
as a preliminary pre-clinical model to assess 
proof-of-principle.
One of the fundamental aspects of cardiac tis-
sue engineering is to develop a bioprosthesis 
with a good adaptability to the damaged myo-
cardium. In our experiments, we observed good 
adaptability of the bioactive implant to the 
underlying myocardium via macroscopic analy-
sis and histology (Figure 2). PCLMA membranes 
have a comparable resistivity to healthy trans-
mural myocardium (440 Ω and 300-700 Ω of 
impedance at a pacing pulse of 1 V, 0.5 ms, 
respectively) [29, 30], suggesting that PCLMA 
electrical resistivity may facilitate the propaga-
tion of electrical pulses throughout the contact 
area between the bioactive implant and the 
infarcted zone. Moreover, PCLMA elastomeric 
membranes support the survival and adhesion 
of neural cells [31] and articular chondrocytes 
[21]. Although not all the implanted cells sur-
vived in the present investigation, the cardiac 
environment that they encountered and the 
properties of the bioactive implant facilitated 
their differentiation toward cardiac lineages, as 
reflected by cTnI expression. The PCLMA mem-
brane presents a micropore structure and size 
(in the 100 μm range) that facilitates the diffu-
sion of nutrients and molecular stimuli from the 
host tissue to the bioactive implant, enabling 
the cells to survive and differentiate [21].
Figure 3. Cardiac functional 
analysis. Representative imag-
es and measurements of the 
LVEF of control-MI (A) and bio-
active implant-treated animals 
(MI-bioimplant) (B) in short 
axis M-mode. (C) Percentage 
of LVEF relative change in in-
farcted groups (control-MI, MI-
scaffold, and MI-bioimplant) 
expressed as the differences 
between the post-MI and pre-
sacrifice values.
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Self-assembling peptide hydrogels are synthet-
ic materials that undergo spontaneous assem-
bly into ordered nanostructures [32-34]. 
Incorporating a self-assembling peptide hydro-
gel (RAD16-I) into the PCLMA elastomeric 
membrane improves the characteristics of the 
bioactive implant in terms of cell survival and 
differentiation, as demonstrated in previous 
studies [35-37]. Injection of a self-assembling 
peptide hydrogel with neonatal rat cardiomyo-
cytes into the rat model of MI previously dem-
onstrated benefits in cardiac function and sur-
vival of the injected cells [38]. More importantly, 
self-assembling peptides also promote differ-
entiation into cardiomyocytes and vascular 
smooth muscle cells when injected with cardiac 
progenitors in a mouse MI model [39]. These 
observations suggest that self-assembling pep-
tide hydrogels are effective for the delivery of 
various cell types for use in cardiac regenera-
tion therapy. Moreover, when combined with 
elastomeric membranes, the hydrogel improves 
cell distribution, facilitating uniform coloniza-
tion of the membrane pores and cell prolifera-
tion [24]. In the present investigation, we also 
observed uniform distribution of the subATD-
PCs inside the bioactive implant and differenti-
ation into the cardiac lineage.
Vascularization of the bioactive implant is also 
important. Interestingly, here the bioimplant 
was fully vascularized with functional vessels 
coming from the myocardium, as demonstrated 
by the presence of FITC-dextran in the lumen of 
the vessels in the bioactive implant. Proper 
vascularization is fundamental for cell survival 
and for integration of the bioprosthesis over the 
myocardium. Here, channeled scaffolds were 
produced with the aim to guide the capillary 
network of the host tissue. Additionally, in vitro 
studies have demonstrated that RAD16-I facili-
tates the adhesion of endothelial cells, their 
proliferation, and capillary formation [40, 41]. 
Moreover, we previously showed that subATD-
PCS have the capacity to differentiate into the 
endothelial lineage when implanted over 
infarcted mouse myocardium [23].
Positive effects on global cardiac motility were 
observed via echocardiography in the present 
investigation. We postulate that a paracrine 
effect comes from the implanted subATDPCs, 
as previously demonstrated [25]. Also, impor-
tant gene expression changes were previously 
found in areas distal from the infarction in dog 
and swine models, suggesting that the benefits 
of bioimplants are not only due to local reduc-
tion in scar size, but to a more general event 
[42, 43].
In conclusion, here we propose a new myocar-
dial bioprosthesis consisting of PCLMA elasto-
meric membrane, RAD16-I peptide hydrogel, 
and subATDPCs. The membrane provides the 
shape, stability and mechanical resistance, the 
RAD16-I peptide hydrogel a suitable cellular 
microenvironment that mimics the extracellular 
matrix, enabling cells to survive and differenti-
ate into cardiac lineage. We believe that this 
bioactive implant is an approximation of a suit-
able platform for supporting cell delivery over 
the infarcted myocardium to promote regenera-
tion after ischemic damage.
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